UNSPSC 51143216: Nicotine hydrochloride

This classification denotes a nicotinic agonist and alkaloid with the molecular formula C10H14N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ELZ2L53YNE, chemically known as nicotine monohydrochloride, (-)-, but more generally known as nicotine hydrochloride, which bears US NIH Compound Identifier 17784. European Medicines Agency schedules nicotine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14645MIG.

Most nations, for tariff purposes, schedule nicotine hydrochloride under HS 29399990. SMILES: CN1CCC[C@H]1C2CCCNC2.CL.

UNSPSC 51143216 Nicotine hydrochloride is a Commodity code that in practice maps to pharmaceutical and health-related products that state and local governments procure for community health and social service programs. The recent opportunities tagged under this code show a mismatch between the nominal commodity name and actual buying activity — Seminole County, Florida's IFB solicited naloxone and drug deactivation systems for harm-reduction support, and the Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer pharmaceutical prescriptions. Neither solicitation involves nicotine hydrochloride specifically. The code sees activity from county health departments and state health and human services agencies pursuing therapeutic medications and prescription fulfillment solutions to support public health initiatives.

Activity under this code is sparse and geographically scattered. The two most recent opportunities span Florida and Texas, with no pattern of concentrated repeat buying in either jurisdiction. Seminole County's IFB (No. IFB60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 drug deactivation systems annually on a fixed-fee basis with quarterly deliveries, a two-year initial term, and a one-year renewal option. The Texas Health and Human Services Commission's RFI (No. HHS0017013), posted April 3, 2026, solicited vendor input on direct-to-manufacturer prescription programs for self-insured employee plans but did not establish formal evaluation criteria, timelines, or award values. The code shows little relevant recent activity and warrants further monitoring rather than active pursuit at this time.